Skip to main content
GENEDRIVE PLC logo

GENEDRIVE PLC — Investor Relations & Filings

Ticker · GDR ISIN · GB00B1VKB244 LEI · 213800ZYODIRZ87Y4K14 IL Manufacturing
Open in API
Filings indexed 606 across all filing types
Latest filing 2026-05-05 Business and Financial …
Country GB United Kingdom
Listing IL GDR

About GENEDRIVE PLC

https://genedriveplc.com/

Genedrive PLC is a molecular diagnostics company specializing in the development and commercialization of a rapid, point-of-care pharmacogenetic testing platform. The company's core technology, the Genedrive® System, is designed for the swift diagnosis of genetic variants to enable personalized medicine in critical care settings. Its key products include the Genedrive® MT-RNR1 ID Kit, used to prevent antibiotic-induced hearing loss in infants, and the Genedrive® CYP2C19 ID Kit, which helps optimize antiplatelet therapy for stroke patients. The platform empowers clinicians to make safer and more effective treatment decisions by providing crucial genetic information at the point of need, thereby improving patient outcomes.

Recent filings

Filing Released Lang Actions
Sussex NHS Trust transitions MT-RNR1 test to BAU
Business and Financial Review
2026-05-05 English
NHS England commercial strategy for MT-RNR1
Regulatory Filings Classification · 1% confidence The document is an RNS announcement by genedrive plc regarding a NHS England preliminary market engagement notice. It does not present financial results, management changes, M&A activity, dividends, or any other specific report content. It is not announcing or attaching a formal Annual Report or Interim Report, nor a dividend or share transaction. As a general corporate announcement published via the London Stock Exchange’s RNS platform and not fitting any more specific category, it falls under Regulatory Filings (RNS).
2026-04-21 English
Interactive Investor Hub Updates
Regulatory Filings Classification · 1% confidence The document is a short RNS press release (AIM: GDR) announcing the update of an interactive investor hub and contains no financial results, no AGM materials, no board changes, no dividends, no share issues, nor references to a formal report being published. It is a general regulatory announcement that does not fit other specific categories, so it defaults to Regulatory Filings (RNS).
2026-04-20 English
Interim Results to 31 December 2025
Interim / Quarterly Report Classification · 1% confidence The document is titled 'Interim results to 31 December 2025' and contains detailed operational highlights, financial highlights (including revenue, operating loss, and cash position), and a 'Chief Executive Officer's and Chairman's Report'. It provides substantive financial data and analysis for a six-month period, which fits the definition of an Interim/Quarterly Report (IR). It is not a mere announcement of a report (RPA) as it contains the full content of the interim results. H2 2025
2026-03-30 English
Holding(s) in Company
Major Shareholding Notification Classification · 1% confidence The document is a 'TR-1: Standard form for notification of major holdings' filed by Genedrive PLC. It explicitly details a change in voting rights held by a shareholder (Robert English) crossing a threshold, which is the standard format for a Major Shareholding Notification (MRQ).
2026-03-12 English
Holding(s) in Company
Major Shareholding Notification Classification · 1% confidence The document is a 'TR-1: Standard form for notification of major holdings' filed by Genedrive PLC. It details a change in voting rights held by a major shareholder (Mr. David Nugent). This type of regulatory disclosure, which reports significant changes in share ownership levels, is classified as a Major Shareholding Notification (MRQ).
2026-03-12 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.